Last reviewed · How we verify
Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]
Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] is a Sulfonamide antibiotic combination Small molecule drug developed by Fundacion Clinic per a la Recerca Biomédica. It is currently FDA-approved for Urinary tract infections, Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Acute otitis media.
Sulfamethoxazole and trimethoprim are synergistic antibiotics that inhibit bacterial folate synthesis by blocking dihydropteroate synthase and dihydrofolate reductase, respectively.
Sulfamethoxazole and trimethoprim are synergistic antibiotics that inhibit bacterial folate synthesis by blocking dihydropteroate synthase and dihydrofolate reductase, respectively. Used for Urinary tract infections, Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Acute otitis media.
At a glance
| Generic name | Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] |
|---|---|
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Drug class | Sulfonamide antibiotic combination |
| Target | Dihydropteroate synthase and dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Sulfamethoxazole is a sulfonamide that inhibits dihydropteroate synthase, preventing the formation of dihydrofolate from para-aminobenzoic acid. Trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolate to tetrahydrofolate. Together, they create a sequential blockade of bacterial folate metabolism, which is essential for nucleotide synthesis and bacterial DNA replication.
Approved indications
- Urinary tract infections
- Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment
- Acute otitis media
- Traveler's diarrhea
- Toxoplasmosis
- Bacterial infections susceptible to the combination
Common side effects
- Rash
- Nausea
- Vomiting
- Diarrhea
- Hyperkalemia
- Stevens-Johnson syndrome
- Hepatotoxicity
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] CI brief — competitive landscape report
- Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] updates RSS · CI watch RSS
- Fundacion Clinic per a la Recerca Biomédica portfolio CI
Frequently asked questions about Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]
What is Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]?
How does Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] work?
What is Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] used for?
Who makes Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]?
What drug class is Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] in?
What development phase is Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] in?
What are the side effects of Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]?
What does Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] target?
Related
- Drug class: All Sulfonamide antibiotic combination drugs
- Target: All drugs targeting Dihydropteroate synthase and dihydrofolate reductase
- Manufacturer: Fundacion Clinic per a la Recerca Biomédica — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Urinary tract infections
- Indication: Drugs for Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment
- Indication: Drugs for Acute otitis media
- Compare: Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] vs similar drugs
- Pricing: Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] cost, discount & access